Axonics Modulation Technologies Stock Forecast, Price & News

Axonics Modulation Technologies' stock was trading at $30.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXNX shares have increased by 46.5% and is now trading at $44.26.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Axonics Modulation Technologies or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Axonics Modulation Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axonics Modulation Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Axonics Modulation Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Axonics Modulation Technologies.

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.28. The business earned $35.24 million during the quarter, compared to analyst estimates of $22.95 million. Axonics Modulation Technologies had a negative net margin of 76.62% and a negative return on equity of 28.05%. The company's quarterly revenue was up 2592.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.89) earnings per share.
View Axonics Modulation Technologies' earnings history.

8 Wall Street analysts have issued 12-month target prices for Axonics Modulation Technologies' shares. Their forecasts range from $48.00 to $77.00. On average, they expect Axonics Modulation Technologies' share price to reach $58.89 in the next twelve months. This suggests a possible upside of 33.1% from the stock's current price.
View analysts' price targets for Axonics Modulation Technologies.

Some companies that are related to Axonics Modulation Technologies include Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Tandem Diabetes Care (TNDM), Nevro (NVRO), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Integra LifeSciences (IART), ICU Medical (ICUI), Merit Medical Systems (MMSI), ShockWave Medical (SWAV), Inari Medical (NARI), Glaukos (GKOS), Cantel Medical (CMD) and NuVasive (NUVA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

Axonics Modulation Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.41%), AXA S.A. (3.37%), Lord Abbett & CO. LLC (3.19%), Polar Capital LLP (2.57%), Polar Capital LLP (2.57%) and State Street Corp (1.96%). Company insiders that own Axonics Modulation Technologies stock include Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen and Rinda Sama.
View institutional ownership trends for Axonics Modulation Technologies.

AXNX stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, AXA S.A., Thrivent Financial for Lutherans, Peregrine Capital Management LLC, Iron Triangle Partners LP, First Trust Advisors LP, Polar Capital LLP, and Polar Capital LLP. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raymond W Cohen, and Rinda Sama.
View insider buying and selling activity for Axonics Modulation Technologies.

AXNX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Columbus Circle Investors, BlackRock Inc., Federated Hermes Inc., WINTON GROUP Ltd, Castleark Management LLC, Advisory Research Inc., and State Street Corp. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Nancy Lynn Md Snyderman, and Raymond W Cohen.
View insider buying and selling activity for Axonics Modulation Technologies.

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXNX stock can currently be purchased for approximately $44.26.

Axonics Modulation Technologies has a market capitalization of $1.76 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Axonics Modulation Technologies employs 302 workers across the globe.

The official website for Axonics Modulation Technologies is www.axonics.com.

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322 or via email at [email protected]